The potential of biomarkers of fibrosis in chronic lung allograft dysfunction

Eline A van der Ploeg*, Barbro N Melgert, Janette K Burgess, C Tji Gan

*Bijbehorende auteur voor dit werk

Onderzoeksoutput: Review articleAcademicpeer review

4 Downloads (Pure)


Chronic lung allograft dysfunction (CLAD) is the major long-term cause of morbidity and mortality after lung transplantation. Both bronchiolitis obliterans syndrome and restrictive lung allograft syndrome, two main types of CLAD, lead to fibrosis in either the small airways or alveoli and pleura. Pathological pathways in CLAD and other types of fibrosis, for example idiopathic pulmonary fibrosis, are assumed to overlap and therefore fibrosis biomarkers could aid in the early detection of CLAD. These biomarkers could help to differentiate between different phenotypes of CLAD and could, in comparison to biomarkers of inflammation, possibly distinguish an infectious event from CLAD when a decline in lung function is present. This review gives an overview of known CLAD specific biomarkers, describes new promising fibrosis biomarkers currently investigated in other types of fibrosis, and discusses the possible use of these fibrosis biomarkers for CLAD.

Originele taal-2English
Aantal pagina's11
TijdschriftTransplantation Reviews
Nummer van het tijdschrift3
Vroegere onlinedatum2021
StatusPublished - 3-jul-2021

Citeer dit